BeiGene appoints Shalini Sharp to Board of Directors effective September 27, 2024

BeOne Medicines Ltd.

Shalini Sharp, aged 49, appointed to fill vacancy on board expanded to 12 members.
Former CFO of Ultragenyx Pharmaceuticals (2012-2020) and board member of Neurocrine Biosciences and Organon.
Will receive equity awards valued at $400,000, annual cash compensation of $65,000 plus $17,500 for Audit Committee service.
Appointment effective September 27, 2024; she will serve as Class III director until 2025 annual meeting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shalini Sharp

Director

ONC · BeOne Medicines Ltd.

Effective: 2024-09-27
Filed: September 26, 2024, 7:59 PM ET

appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Shalini Sharp was appointed as Director at BeOne Medicines Ltd..

Action: appointed
Role: Director

Exact text from the filing

appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.

View on SEC.gov

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-24-000118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.